The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
复制标题
DOI：
10.1111/jvh.12173
复制
发表时间：
2013-11
影响因子：
2.5
通讯作者：
New Paradigm of HCV Therapy Meeting Participants
中科院分区：
文献类型：
--
作者：
Afdhal NH;Zeuzem S;Schooley RT;Thomas DL;Ward JW;Litwin AH;Razavi H;Castera L;Poynard T;Muir A;Mehta SH;Dee L;Graham C;Church DR;Talal AH;Sulkowski MS;Jacobson IM;New Paradigm of HCV Therapy Meeting Participants
总结：新的数据表明，慢性丙型肝炎病毒（HCV）的全口服抗病毒治疗将在不久的将来成为现实。 在替代基于干扰素的治疗中，全口服方案预期更耐受、更有效、持续时间更短且更易于管理。与新的治疗方案相一致的是疾病筛查和分期的新方法，这为更及时的护理和治疗创造了可能性。组织学损伤的评估通常使用肝活检进行，但组织学损伤的非侵入性评估已成为一些欧洲国家的标准，在美国也越来越普遍。疾病控制和预防中心（CDC）的新举措也已到位，以简化检测，提高提供者和患者的认识，并将HCV筛查的建议扩展到基于风险的战略之外。2012年发布的CDC建议旨在通过建议对1945-1965年出生的所有人进行一次性检测，增加美国HCV负担最大的人群的HCV检测。2013年，美国预防服务工作组（英语：United States Preventive Services Task Force）通过了类似的基于风险和基于出生队列的检测建议。总的来说，筛查、诊断和治疗的发展可能会增加对治疗的需求，并刺激与慢性HCV相关的护理服务的转变，增加初级保健和传染病专家的参与。然而，即使在这个治疗的新时代，治愈HCV患者的障碍仍然存在。要克服这些障碍，就需要在地方、区域和国家各级采取新的综合战略并投入资源。
SUMMARY. Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in duration and simpler to administer. Coinciding with new treatment options are novel methodologies for disease screening and staging, which create the possibility of more timely care and treatment. Assessments of histologic damage typically are performed using liver biopsy, yet noninvasive assessments of histologic damage have become the norm in some European countries and are becoming more widespread in the United States. Also in place are new Centers for Disease Control and Prevention (CDC) initiatives to simplify testing, improve provider and patient awareness and expand recommendations for HCV screening beyond risk-based strategies. Issued in 2012, the CDC recommendations aim to increase HCV testing among those with the greatest HCV burden in the United States by recommending one-time testing for all persons born during 1945–1965. In 2013, the United States Preventive Services Task Force adopted similar recommendations for risk-based and birth-cohort-based testing. Taken together, the developments in screening, diagnosis and treatment will likely increase demand for therapy and stimulate a shift in delivery of care related to chronic HCV, with increased involvement of primary care and infectious disease specialists. Yet even in this new era of therapy, barriers to curing patients of HCV will exist. Overcoming such barriers will require novel, integrative strategies and investment of resources at local, regional and national levels.
登录
查看更多内容
影响因子：
2.4
作者：
Baranova A;Lal P;Birerdinc A;Younossi ZM
通讯作者：
Younossi ZM
影响因子：
11.8
作者：
Alavi, Maryam;Grebely, Jason;Dore, Gregory J.
通讯作者：
Dore, Gregory J.
DOI：
10.1097/01.qai.0000131932.21612.49
发表时间：
2004-11-01
影响因子：
3.6
作者：
Fishbein, DA;Lo, YT;Klein, RS
通讯作者：
Klein, RS
DOI：
10.1111/j.1572-0241.2003.t01-1-07641.x
发表时间：
2003-09-01
影响因子：
9.8
作者：
Di Bisceglie, AM;Lyra, AC;Befeler, AS
通讯作者：
Befeler, AS
影响因子：
39.2
作者：
Falck-Ytter, Y;Kale, H;McCullough, AJ
通讯作者：
McCullough, AJ